Per Centers for Disease Control and Prevention (CDC) guidelines, a definitive diagnosis of neurosyphilis requires compatible neurological manifestations corroborated by cerebrospinal fluid (CSF) analysis (e.g., a reactive CSF-VDRL test)
While not all reported cases involve off-label or non-prescribed use, doctors highlighted the dangers of unsupervised dosing and improper titration
Ultomiris (ravulizumab-cwvz) Indication(s): Multiple rare, complement-mediated disorders, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD) Manufacturer(s): Alexion/AstraZeneca 2024 Sales: $3.92 billion Why it sold so well: Ultomiris, developed by Alexion, AstraZeneca Rare Disease, is emerging as a hematology drug to watch in 2025, driven by strong commercial momentum and expanding clinical uptake in 2024
Occurs alongside persistent low mood, anxiety or significant sleep changes
